Anzeige
Mehr »
Montag, 12.01.2026 - Börsentäglich über 12.000 News
Kritischer Rohstoff, westliche Knappheit, hohe Gehalte: Steht hier die nächste strategische Neubewertung bevor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GA | ISIN: BMG0360L1349 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALTAMIRA THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ALTAMIRA THERAPEUTICS LTD 5-Tage-Chart

Aktuelle News zur ALTAMIRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.12.25Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China331Regulatory clearance of Bentrio in allergic rhinitis for Mainland ChinaNearly 200 million Chinese estimated to suffer from allergic rhinitisBentrio to be launched by partner Nuance Pharma HAMILTON,...
► Artikel lesen
20.11.25Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation637Conformity with stringent new EU regulations for medical devices confirmedAllows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countriesMajor...
► Artikel lesen
03.11.25Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules234Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and growing...
► Artikel lesen
ALTAMIRA THERAPEUTICS Aktie jetzt für 0€ handeln
29.08.25Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer5
29.08.25Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results654Company to host webcast today at 8.00 a.m. ETGrowing portfolio of RNA delivery clients and programsAdvancing plans for partial spin-off of RNA delivery activitiesContinued adjustment of cost structure...
► Artikel lesen
26.08.25Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025330HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology...
► Artikel lesen
15.07.25Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine226HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet medical...
► Artikel lesen
11.06.25Delisting of Securities of Blue Star Foods Corp.; Altamira Therapeutics Ltd.; Evergreen Corporation; Fresh2 Group Limited; Coliseum Acquisition Corp.; The Real Good Food Company, Inc.; Mynaric AG; byNordic Acquisition Corporation; ...856NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Blue Star Foods Corp. Blue Star Foods Corp.'s stock was suspended on December...
► Artikel lesen
30.04.25Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results452Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDTRNA delivery business progressing with platform development, new applications...
► Artikel lesen
22.01.25Altamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies286Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira's RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1